Gabapentin Treatment of Cannabis Dependence

• Status: Completed
• Trial end date: 2016-05-19
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Scripps Research Institute
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

• Males or females from 18-65 years of age

• Meets DSM IV criteria for current cannabis dependence

• Seeking research-based outpatient treatment for cannabis dependence that involves daily medication

• Smoked MJ daily at least 25 days per month during the 90 days prior to randomization

• At least a 2-year history of regular MJ use

Exclusion Criteria:

• Abstinent from cannabis more than 2 days at the time of randomization

• Active suicidal ideation

• Currently meets DSM IV criteria for abuse or dependence on other substances, or has urine drug screen positive for substances, other than cannabis or nicotine

• Significant medical disorders that will increase potential risk or interfere with study participation,

• Sexually active female participants with childbearing potential who are pregnant, nursing or refuse to use a reliable method of birth control

• Meets DSM IV criteria for a major AXIS I disorder other than cannabis and nicotine dependence,

• Inability to understand and/or comply with the provisions of the protocol and consent form

• Treatment with an investigational drug during the previous month

• Sensitivity to study drug as evidenced by adverse drug experiences with gabapentin or its ingredients

• Ongoing treatment with medications that may affect study outcomes